10
views
0
recommends
+1 Recommend
0 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          The tumor suppressor p53 plays a central role in mediating the cellular response to stress and DNA damage. p53 is a tetramer containing both structured and intrinsically disordered domains that function synergistically to regulate p53 activity. Using intein technology and NMR spectroscopy, we show that the disordered N-terminal transactivation domain of p53 makes intramolecular interactions with the structured DNA-binding domain. These interactions impair binding of p53 to nonspecific DNA sequences but not to p53-specific DNA sequences, providing a means whereby p53 can discriminate more effectively between cognate sites and the vastly more abundant noncognate sites in the genome.

          Abstract

          Atomic resolution characterization of the full-length p53 tetramer has been hampered by its size and the presence of extensive intrinsically disordered regions at both the N and C termini. As a consequence, the structural characteristics and dynamics of the disordered regions are poorly understood within the context of the intact p53 tetramer. Here we apply trans-intein splicing to generate segmentally 15N-labeled full-length p53 constructs in which only the resonances of the N-terminal transactivation domain (NTAD) are visible in NMR spectra, allowing us to observe this region of p53 with unprecedented detail within the tetramer. The N-terminal region is dynamically disordered in the full-length p53 tetramer, fluctuating between states in which it is free and fully exposed to solvent and states in which it makes transient contacts with the DNA-binding domain (DBD). Chemical-shift changes and paramagnetic spin-labeling experiments reveal that the amphipathic AD1 and AD2 motifs of the NTAD interact with the DNA-binding surface of the DBD through primarily electrostatic interactions. Importantly, this interaction inhibits binding of nonspecific DNA to the DBD while having no effect on binding to a specific p53 recognition element. We conclude that the NTAD:DBD interaction functions to enhance selectivity toward target genes by inhibiting binding to nonspecific sites in genomic DNA. This work provides some of the highest-resolution data on the disordered N terminus of the nearly 180-kDa full-length p53 tetramer and demonstrates a regulatory mechanism by which the N terminus of p53 transiently interacts with the DBD to enhance target site discrimination.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Structural biology of the tumor suppressor p53.

          The tumor suppressor protein p53 induces or represses the expression of a variety of target genes involved in cell cycle control, senescence, and apoptosis in response to oncogenic or other cellular stress signals. It exerts its function as guardian of the genome through an intricate interplay of independently folded and intrinsically disordered functional domains. In this review, we provide insights into the structural complexity of p53, the molecular mechanisms of its inactivation in cancer, and therapeutic strategies for the pharmacological rescue of p53 function in tumors. p53 emerges as a paradigm for a more general understanding of the structural organization of modular proteins and the effects of disease-causing mutations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

            The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription. In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53. The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix. The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft. These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain. The structure also suggests that the amphipathic alpha helix may be a common structural motif in the binding of a diverse family of transactivation factors to the TATA-binding protein-associated factors.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                27 November 2018
                12 November 2018
                : 115
                : 48
                : E11302-E11310
                Affiliations
                [1] aDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute , La Jolla, CA 92037;
                [2] bSkaggs Institute for Chemical Biology, The Scripps Research Institute , La Jolla, CA 92037
                Author notes
                1To whom correspondence should be addressed. Email: wright@ 123456scripps.edu .

                Contributed by Peter E. Wright, October 16, 2018 (sent for review August 15, 2018; reviewed by Carol Prives and Ichio Shimada)

                Author contributions: A.S.K. and P.E.W. designed research; A.S.K. performed research; A.S.K., H.J.D., and P.E.W. analyzed data; and A.S.K., H.J.D., and P.E.W. wrote the paper.

                Reviewers: C.P., Columbia University; and I.S., The University of Tokyo.

                Author information
                http://orcid.org/0000-0001-6855-3398
                http://orcid.org/0000-0002-1368-0223
                Article
                PMC6275486 PMC6275486 6275486 201814051
                10.1073/pnas.1814051115
                6275486
                30420502
                635f5ae3-ad79-47e2-ace2-bb91489e769f
                Copyright @ 2018

                Published under the PNAS license.

                History
                Page count
                Pages: 9
                Funding
                Funded by: HHS | NIH | National Cancer Institute (NCI) 100000054
                Award ID: CA096865
                Award Recipient : Peter E. Wright
                Funded by: HHS | NIH | National Institute of General Medical Sciences (NIGMS) 100000057
                Award ID: GM075995
                Award Recipient : Peter E. Wright
                Categories
                PNAS Plus
                Biological Sciences
                Biophysics and Computational Biology
                PNAS Plus

                intrinsically disordered protein,DNA recognition,transcription factor,segmental isotope labeling,intein

                Comments

                Comment on this article